AI assistant
Sending…
Intellia Therapeutics, Inc. — Director's Dealing 2021
Dec 29, 2021
31767_dirs_2021-12-29_23d65ae5-37f5-4fe9-ac84-849ec63d04d5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Intellia Therapeutics, Inc. (NTLA)
CIK: 0001652130
Period of Report: 2021-12-20
Reporting Person: Hicks Derek (EVP, Chief Business Officer)
More from Intellia Therapeutics, Inc.
Interim / Quarterly Report
2026
May 11
Regulatory Filings
2026
May 11
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 29
Regulatory Filings
2026
Apr 27
Regulatory Filings
2026
Apr 27
Regulatory Filings
2026
Apr 10
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3